Legal Basis for Marketing Authorization in the EEA

Navigating the regulatory landscape for drug approval in the European Economic Area (EEA) can be complex. There are multiple legal pathways, each with its own requirements, especially around clinical studies. Here’s a quick snapshot:

Full Applications (Article 8(3) of Directive 2001/83/EC) require comprehensive clinical data for new products.

Generic Applications (Article 10(1) of Directive 2001/83/EC) do not require new clinical studies but may require bioequivalence studies.

Hybrid Applications (Article 10(3) of Directive 2001/83/EC) involve some clinical studies to support changes from the reference product.

Well-Established Use Applications (Article 10a of Directive 2001/83/EC) rely on existing literature, avoiding the need for new clinical trials.

Fixed-Combination Applications (Article 10b of Directive 2001/83/EC) necessitate some clinical data for the combination.

Informed Consent Applications (Article 10c of Directive 2001/83/EC) do not require new studies if based on an existing authorized product.

Biosimilar Applications (Article 10(4) of Directive 2001/83/EC) require clinical studies to establish comparability to the reference product.

Orphan Drug Applications (Regulation (EC) No 141/2000) involve clinical studies to prove efficacy and safety, similar to other pathways, but may benefit from regulatory incentives due to the target population.

Choosing the right pathway ensures compliance while optimizing time and resources.

This table provides a clear overview of the different legal bases for marketing authorization in the EEA, along with the corresponding clinical study requirements and relevant examples.


Read also:


Resource Person: Bhupesh Pratap

Leave a Comment